Key Insights

Highlights

Treatment Research

2 treatments under study, led by Clindamycin

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 1 (1)
Phase 2 (1)

Trial Status

Active Not Recruiting1
Unknown1

Clinical Trials (2)

Research Network

Common Treatments

  • Clindamycin1
  • Lcfa011

Active Sponsors

  • Meilin Zhu, PhD, Massachusetts General Hospital1
  • Caroline Mitchell, MD, MPH, Massachusetts General Hospital1
  • Massachusetts General Hospital1
  • Zagazig University1

Top Investigators

Activity Timeline